BTP0717

Part I study: Main purpose: To evaluate the safety and tolerability of LXH-2301 in single/multiple oral administration in healthy adult subjects; Secondary purpose: To evaluate the PK and PD characteristics of LXH-2301 and positive control drugs in single/multiple oral administration in healthy adult subjects. Part II study: Main purpose: To evaluate the PK and PD characteristics of LXH-2301 and positive control drugs in single/multiple oral administration in gout patients who have not undergone alkalinization of urine and uric acid-lowering drug treatment and are in remission, as well as its effectiveness in alkalinizing urine, so as to provide a basis for the selection of clinical dosage and administration method for this product; Secondary purpose: To evaluate the safety and tolerability of LXH-2301 in single/multiple oral administration in gout patients who have not undergone alkalinization of urine and uric acid-lowering drug treatment and are in remission; Exploratory purpose: To evaluate the effectiveness of LXH-2301 in lowering uric acid levels when used alone.

Primary objective: To evaluate the effect of diet (high-fat meal) on the pharmacokinetics of LXH-2301 in healthy adult subjects after a single oral administration; Secondary objective: To evaluate the pharmacokinetic characteristics, safety and tolerability of LXH-2301 in healthy adult subjects after a single oral administration on an empty stomach or after a meal.